The tp53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non–small cell lung cancer

Abstract

In a small cohort of patients with advanced non-small cell lung cancer we found a direct link between normal TP53 genotype and response to cisplatin-based induction treatment and also between mutant genotype and resistance to treatment, whereas p53 immunohistochemical result was predictive of neither.

Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers

“…34,35 Interestingly, TP53 mutations have been found to be associated with resistance to cisplatin combined with etoposide 36 in nonsmall cell lung cancer as well as to cisplatin combined with ifosfamide. 37 The results from the former study 36 may be consistent with the observations regarding anthracyclines in as much as etoposide, being a Topo-II inhibitor, resembles the anthracyclines with respect to mechanism of action. Ifosfamide, on the contrary, is metabolized into cyclophosphamide in vivo.…”

Long-term survival results of non-small cell lung cancer patients with complete pathological response after neoadjuvant therapy

“…In particular, patients who had regression in N 2 disease and underwent complete resection are reported to have better prognosis. [3][4][5][6][7][8][9] The issue is to be able to clearly detect the nodal status preoperatively and the degree of the response to the neoadjuvant treatment regimen. It is mandatory to perform PET/CT and evaluate the results and obtain samples from the nodal involvement areas using invasive methods.…”

“…Patients that received high dose radiotherapy in addition to chemotherapy are reported to have complete pathological response rates up to 55%. [5][6][7][8][9][18][19][20][21][22][23][24][25][26] Pathologically complete or near complete response is reported to be a prognostic factor by some authors. [10][11][12][13][14] Although prognosis is preferably good in this group of patients, distant recurrences in particular may reduce success rates.…”

“…However, the generally accepted opinion is that patients who have no findings of N 2 disease and who undergo complete resection benefit the most. [3][4][5][6][7][8][9] Various studies have demonstrated that a pathologically complete or near complete response is also one of the important prognostic factors. [10][11][12][13][14] There is no certainty about the evaluation of complete response after treatment.…”

Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in stage III non-small cell lung cancer.

“…18 Chemotherapy and concurrent radiation is the standard therapy for inoperable Stage III NSCLC, but the five year overall survival (OS) remains poor, that is, 20% and 8% for IIIA and IIIB disease, respectively. 19 Such an aggressive malignant phenotype has been hypothesized to stem from an innate resistance of NSCLC to chemotherapy 20,21 and to its ability to evade immunosurveillance. 22,23 However, the role of IDO in mediating immune tolerance in NSCLC is unclear.…”